|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The profile of gene expression of human marrow mesenchymal stem cells显示文摘 | WAKITANI A S DIMAS T C Jr | 2003 | Stem cells2003，21，： | 1 |
| 2 | The profile of gene expression of human marrow mesenchymal stem cells显示文摘 | Wilson AS Jr Dimas TC | 2003 | Stem Cells2003，21，： | 1 |
| 3 | Surgical pocket location for gluteal implants:a systematic review显示文摘 | Flores-Lima G Eppley BL Dimas JR | 2013 | Aesthet Plast Surg2013，37，2： | 1 |
| 4 | Transplacental pharmacokinetics of flecainide in the gravid baboon and fetus 显示文摘 | Dimas VV Taylor MD Cunnyngham CB Overhoh ED Bourne DW Stanely JR 3rd | 2005 | Pediatr Cardiol2005，26，6： | 1 |
| 5 | The profile of gene expression of human marrow mesenchymal stem cells显示文摘 | WAKITANI A S JR DIMAS T C | 2003 | Stem cells2003，21，： | 1 |
| 6 | The profile of gene expression of human marrow mesenchymal stem cells显示文摘 | Wilson AS Jr Dimas TC | 2003 | Stem Cells2003，21，5： | 1 |
| 7 | The profile of gene expression of human marrow mesenchymal stem cells显示文摘 | Wilson AS Jr Dimas TC | 2003 | Stem Cells2003，21，： | 1 |
| 8 | The profile of gene expression of human marrow mesenchymal stem cells显示文摘 | Wilson AS Jr Dimas TC | 2003 | Stem Cells2003，21，： | 1 |
| 9 | Notes,outline and divergence times of Basidiomycota显示文摘The Basidiomycota constitutes a major phylum of the kingdom Fungi and is second in species numbers to the Ascomycota.The present work provides an overview of all validly published,currently used basidiomycete genera to date in a single document.An outline of all genera of Basidiomycota is provided,which includes 1928 currently used genera names,with 1263 synonyms,which are distributed in 241 families,68 orders,18 classes and four subphyla.We provide brief notes for each accepted genus including information on classification,number of accepted species,type species,life mode,habitat,distribution,and sequence information.Furthermore,three phylogenetic analyses with combined LSU,SSU,5.8s,rpb1,rpb2,and ef1 datasets for the subphyla Agaricomycotina,Pucciniomycotina and Ustilaginomycotina are conducted,respectively.Divergence time estimates are provided to the family level with 632 species from 62 orders,168 families and 605 genera.Our study indicates that the divergence times of the subphyla in Basidiomycota are 406-430 Mya,classes are 211-383 Mya,and orders are 99-323 Mya,which are largely consistent with previous studies.In this study,all phylogenetically supported families were dated,with the families of Agaricomycotina diverging from 27-178 Mya,Pucciniomycotina from 85-222 Mya,and Ustilaginomycotina from 79-177 Mya.Divergence times as additional criterion in ranking provide additional evidence to resolve taxonomic problems in the Basidiomycota taxonomic system,and also provide a better understanding of their phylogeny and evolution. | Mao-Qiang He Rui-Lin Zhao Kevin D.Hyde Dominik Begerow Martin Kemler Andrey Yurkov Eric H.C.McKenzie Olivier Raspe Makoto Kakishima Santiago Sanchez-Ramırez Else C.Vellinga Roy Halling Viktor Papp Ivan V.Zmitrovich Bart Buyck Damien Ertz Nalin N.Wijayawardene Bao-Kai Cui Nathan Schoutteten Xin-Zhan Liu Tai-Hui Li Yi-Jian Yao Xin-Yu Zhu An-Qi Liu Guo-Jie Li Ming-Zhe Zhang Zhi-Lin Ling Bin Cao Vladimir Antonin Teun Boekhout Bianca Denise Barbosa da Silva Eske De Crop Cony Decock Balint Dima Arun Kumar Dutta Jack W.Fell Jozsef Geml Masoomeh Ghobad-Nejhad Admir J.Giachini Tatiana B.Gibertoni Sergio P.Gorjon Danny Haelewaters Shuang-Hui He Brendan P.Hodkinson Egon Horak Tamotsu Hoshino Alfredo Justo Young Woon Lim Nelson Menolli Jr Armin Mesic Jean-Marc Moncalvo Gregory M.Mueller La szlo G.Nagy RHenrik Nilsson Machiel Noordeloos Jorinde Nuytinck Takamichi Orihara Cheewangkoon Ratchadawan Mario Rajchenberg Alexandre G.S.Silva-Filho Marcelo Aloisio Sulzbacher Zdenko Tkalcec Ricardo Valenzuela Annemieke Verbeken Alfredo Vizzini Felipe Wartchow Tie-Zheng Wei Michael WeiB Chang-Lin Zhao Paul M.Kirk | 2019 | Fungal Diversity2019，，6： | 0 |
| 10 | Lafoensia pacari alleviates intestinal damage by modulating cyclooxygenase-2:In silico and in vivo evaluation in a colitis model显示文摘BACKGROUND Inflammatory bowel diseases(IBD)are a worldwide health problem and mainly affect young people,consequently affecting the workforce.Available treatments are often associated with side effects,and new therapeutic options are needed.For centuries,plants have represented important substrates in the field of drug development.Lafoensia pacari(L.pacari)is a plant whose pharmaceutical potential has been described,and may have biological activity relevant to the treatment of IBD symptoms.AIM To investigate the activity of keto-alcoholic extracts of L.pacari with respect to ameliorating the inflammatory and nociceptive symptoms of acute experimental colitis in mice.METHODS Keto-alcoholic extracts of L.pacari leaves and bark were administered to male andfemale Swiss mice weighing 25 g to 30 g(n=8 male mice and n=8 female mice).The effect of these extracts was observed in an acetic acid-induced acute experimental model of colitis with regard to antinociception/analgesia and inflammatory tissue damage.Recorded macroscopic indices included the Wallace score and the colon weight obtained using a precision scale.Mechanical hyperalgesia was determined using an electronic analgesimeter.Behavior related to overt pain was determined by quantifying the number of writhing instances within 20 min of administration of acetic acid.Molecular docking was performed using human and murine cyclooxygenase-2(COX-2)with 3 flavonoids(ellagic acid,kaempferol,and quercetin)on the AutoDock Vina software.Analysis of variance followed by Tukey’s posttest was used with P<0.05 indicating significance.RESULTS In this murine model of colitis,administration of extracts from L.pacari ameliorated acetic acidinduced writhing and colitis-associated inflammatory pain.These improvements may be attributable to the reduction in edema,inflammation(e.g.,ulcers,hyperemia,and bowel wall damage),and the intensity of abdominal hyperalgesia.The keto-alcoholic extracts of L.pacari leaves and bark administered at a dose of either 100 mg/kg or 300 mg/kg significantly reduced the number of writhing events when compared to the negative control(P<0.05).Additionally,extracts of L.pacari bark also performed better than Dipyrone.Leaf extracts administered at 10 mg/kg,30 mg/kg,and 100 mg/kg and bark extracts administered at 30 mg/kg significantly reduced or prevented the development of edema in the colon of treated mice,while mesalazine did not.Moreover,using molecular docking,we observed that the flavonoids present in L.pacari extracts bind to COX-2,an event not unique to ellagic acid.CONCLUSION The results of this study demonstrate a potential novel application of L.pacari extracts for the reduction of inflammation and promotion of antinociception/analgesia as demonstrated by our findings in a murine model of colitis.These findings were also corroborated by in silico analyses,and suggest that L.pacari extracts may be a promising therapeutic agent in the treatment of IBD. | Gabrielle Caroline Peiter Thayene Kamyli Moesch Queiroz Edson Luiz Michalkiewicz Jr Raphael Henrique Chappuis Jennefer Sousa Luz Luiz Henrique Casagrande Piovezani Cleison Ferreira Silva Matheus Nozomi Tsutumi Augusto Fernandes Chaves Rafael Messias Luiz Cinthia Façanha Wendel Ana Carla Zarpelon-Schutz Kádima Nayara Teixeira | 2023 | World Journal of Gastroenterology2023，29，17： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员